Marine Depsipeptide Nobilamide i Inhibits Cancer Cell Motility and Tumorigenicity via Suppressing Epithelial-Mesenchymal Transition and MMP2/9 Expression

  • Tu Cam Le
  • , Sultan Pulat
  • , Jihye Lee
  • , Geum Jin Kim
  • , Haerin Kim
  • , Eun Young Lee
  • , Prima F. Hillman
  • , Hyukjae Choi
  • , Inho Yang
  • , Dong Chan Oh
  • , Hangun Kim
  • , Sang Jip Nam
  • , William Fenical

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

A cyclic depsipeptide, nobilamide I (1), along with the known peptide A-3302-B/TL-119 (2), was isolated from the saline cultivation of the marine-derived bacterium Saccharomonospora sp., strain CNQ-490. The planar structure of 1 was elucidated by interpretation of 1D and 2D NMR and MS spectroscopic data. The absolute configurations of the amino acids in 1 were assigned by using the C3 Marfey's analysis and comparing them with those of 2 based on their biosynthetic pathways. Nobilamide I (1) decreased cell motility by inhibiting epithelial-mesenchymal transition markers in A549 (lung cancer), AGS (gastric cancer), and Caco2 (colorectal cancer) cell lines. In addition, 1 modulated the expression of the matrix metalloproteinase (MMP) family (MMP2 and MMP9) in the three cell lines.

Original languageEnglish
Pages (from-to)1722-1732
Number of pages11
JournalACS Omega
Volume7
Issue number2
DOIs
StatePublished - 18 Jan 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Published by American Chemical Society.

Fingerprint

Dive into the research topics of 'Marine Depsipeptide Nobilamide i Inhibits Cancer Cell Motility and Tumorigenicity via Suppressing Epithelial-Mesenchymal Transition and MMP2/9 Expression'. Together they form a unique fingerprint.

Cite this